Identification of risk factors associated with onset and progression of amyotrophic lateral sclerosis using systematic review and meta-analysis

Abstract

Although amyotrophic lateral sclerosis (ALS) was identified as a neurological condition 150 years ago, risk factors related to the onset and progression of ALS remain largely unknown. Monogenic mutations in over 30 genes are associated with about 10% of ALS cases. The age at onset of ALS and disease types has been found to influence ALS progression. The present study was designed to identify additional putative risk factors associated with the onset and progression of ALS using systematic review and meta-analysis of observational studies. Risk factors that may be associated with ALS include: 1) genetic mutations, including the intermediate CAG repeat expansion in ATXN2; 2) previous exposure to heavy metals such as lead and mercury; 3) previous exposure to organic chemicals, such as pesticides and solvents; 4) history of electric shock; 5) history of physical trauma/injury (including head trauma/injury); 6) smoking (a weak risk factor for ALS in women); and 6) other risk factors, such as participating in professional sports, lower body mass index, lower educational attainment, or occupations requiring repetitive/strenuous work, military service, exposure to Beta-N-methylamino-l-alanin and viral infections. Risk factors that may be associated with ALS progression rate include: 1) nutritional status, including vitamin D deficiency; 2) comorbidities; 3) ethnicity and genetic factors; 4) lack of supportive care; and 4) smoking. The extent to which these associations may be causal is discussed, with further research recommended to strengthen the evidence on which determinations of causality may be based.

Introduction

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative condition affecting the voluntary motor nervous system (Sathasivam, 2010, Piaceri et al., 2011, Talman et al., 2009). The typical symptoms/signs in ALS patients include progressive atrophic weakness and spasticity of affected regions, and the spread of symptoms from the site(s) of onset. The smooth and striated muscles of sphincters, the muscles responsible for ocular movement, and the sensory nerves (temperature, pain, taste, hearing, vision, olfaction) are usually spared. However, dementia, cognitive impairment and executive dysfunction have been detected in more than 50% of ALS patients (Phukan et al., 2007, Phukan et al., 2011, Gordon et al., 2011b), especially the ALS patients with mutations in the C9orf72 and TDP43 genes (Cooper-Knock et al., 2012, Byrne et al., 2012, Ludolph et al., 2012, Seltman and Matthews, 2012). In most ALS cases, disease progression is rapid. The average survival time from diagnosis is less than 3 years, with affected individuals often dying of respiratory failure or inanition. Notably, a small proportion (∼10%) of ALS cases survive for more than 10 years (Testa et al., 2004), and rare ALS cases have survived for more than 50 years (Tosi et al., 1994). Multiple ALS subsets and ALS variants have been described (Silani et al., 2011, Kim et al., 2009), indicating the heterogeneity of ALS phenotypes (Piaceri et al., 2011, Chio et al., 2011, Turner et al., 2013, Sabatelli et al., 2013). Different phenotypes have been reported among individuals with the same type of gene mutations, such as those of the C9orf72 (Murray et al., 2011, Stewart et al., 2012), SOD1 (Piaceri et al., 2011), TDP43 and/or FUS genes (Mackenzie et al., 2011).

ALS is usually diagnosed within a year of the appearance of the first clinical signs (Mitchell et al., 2010). There is currently no specific diagnostic test for ALS. Instead, diagnosis relies upon consideration of differential diagnoses and the presence of unique clinical signs – upper and lower motor neuron findings confined to spinal and bulbar voluntary muscles. Pathological degeneration signs include lateral sclerosis of descending motor tracts in motor neuron cells in the brainstem and spinal anterior horns. Clinical diagnostic criteria for ALS, referred to as the EI Escorial criteria, were proposed by the World Neurology Federation in 1994, and revised in 2000 and 2008 (Silani et al., 2011). According to these criteria, ALS cases are classified as definite, probable, or possible. The World Health Organization (WHO) categorized ALS as a major subset of motor neuron disease (MND), and all subsets of MND share an identical International Classification of Diseases (ICD) code. Therefore, in the biomedical literature, MND and ALS are often used interchangeably. Misdiagnosis or misclassification has been estimated to account for about 10% of total ALS cases (Silani et al., 2011).

ALS is a degenerative motor neuron disease that is terminal and irreversible. Disease severity can be measured using the ALS functional rating scales (ALSFRS), having a score ranging from 0–40, based on 10 basic functions in 4 key functional domains (swallowing, walking/self-care, communicating and breathing) (Anonymous, 1996). The disease course of ALS has recently been divided into 6 stages, progressing from stage 0 for no loss of function to stage 5 for death (Chio et al., 2013a, Chio et al., 2013b). The progression to death of ALS is apparently slower for spinal ALS than for bulbar onset cases, with the age at onset being negatively associated with survival time (Chio et al., 2009a, Chio et al., 2009b, Chio et al., 2009c).

The crude incidence of ALS in Europe and North America, especially among whites, is quite stable, about 2–3 cases per 100,000 people per year (Cronin et al., 2007, Alonso et al., 2009). Although the incidence of ALS in Asia is generally lower, the highest incidences (50–100 fold greater than the global average) have been reported in Asia, specifically in Guam and the surrounding Pacific islands during the 1940–1960s (Plato et al., 2003, Okamoto et al., 2009b, Spencer et al., 2005, Waring et al., 2004, Steele, 2005, Yoshida et al., 1998). Populations of Hispanic or African origin display lower incidences of ALS (Cronin et al., 2007). Because of the short survival time of ALS patients, the mortality rate of ALS roughly reflects its incidence rate (Marin et al., 2011a).

Both the incidence and prevalence of ALS are greater in men than in women, the ratio being approximately 1.5:1 (McCombe and Henderson, 2010). Male sex is also associated with age of onset and ALS disease type (Gordon et al., 2011a). A preponderance of ALS in males has been reported for respiratory, flail arm, classic and pure lower motor neuron (p-LMN) phenotypes (Chio et al., 2011). This male preponderance has declined in recent decades, suggesting that changing exposure to environmental risk factors for ALS may explain part of this sex difference (Gordon et al., 2011a).

ALS is an age-associated neurodegenerative condition, having some similarities to chronic diseases such as Alzheimer’s disease; however, unlike Alzheimer’s disease, ALS is not strictly an aging-associated condition (Brody and Grant, 2001). The incidence of ALS increases with age, peaks at about 70 years of age, and then declines rapidly thereafter (Logroscino et al., 2008). Although ALS is a rare neurodegenerative condition, it has been reported that the proportion of overall mortality due to ALS has increased in recent decades, more so in women than in men (Gordon et al., 2011a).

ALS cases have been classified as belonging to one of two categories – familial or sporadic, although this classification system is now being challenged. About 10% of sporadic ALS cases are caused by monogenic mutations (Chio et al., 2012). Unlike many other chronic diseases, such as various cancers, sporadic ALS cases are not randomly distributed in the general population. Geographical (Doi et al., 2010, Turabelidze et al., 2008, Malaspina et al., 2002, Ceroni et al., 1999, Poloni et al., 1997, Gunnarsson et al., 1996, Uccelli et al., 2007, Noonan et al., 2005), occupational (Gunnarsson et al., 1996, Barth et al., 2009, Rose and Brix, 2006), and conjugal (Poloni et al., 1997) ALS clusters have been observed, suggesting that shared environmental risk factors also play an important role in the etiology of ALS. Overall, genetic factors and environmental risk factors are considered to have equally important roles in the onset of ALS (Wingo et al., 2011, Al-Chalabi et al., 2010). ALS is one of most heterogeneous neurodegenerative conditions, in terms of etiology, phenotype and progression. Although many genetic and environmental risk factors have been associated with the onset of sporadic ALS in many observational studies, no single gene variant or environmental risk factor has been conclusively linked to the onset of sporadic ALS. To date, few reviews have assessed the risk factors associated with the progression of ALS. It is important for the management of ALS cases that appropriate diagnostic criteria be defined, and that known and unknown risk factors be characterized and described. The objectives of this study were to identify environmental and genetic risk factors that are associated with the onset or progression of ALS through systematic reviews and meta-analyses of observational studies.